Phreesia, a software as a service (SaaS) firm specializing in life sciences and healthcare, has announced its acquisition of MediFind, a health tech company focused on data science. The aim of this acquisition is to enhance the speed and accuracy of matching patients with a wide range of services.
Phreesia provides applications that streamline and automate patient intake processes, and with the integration of MediFind’s machine learning and AI technologies, it will now be able to connect patients with leading experts, clinical trials, health systems, and healthcare technologies through advanced analytics.
By combining the expertise of both companies, the goal is to expedite the process of matching patients with their required healthcare services, particularly for those dealing with serious, chronic, and rare diseases. The integration of MediFind’s capabilities will enable quicker and more precise connections, improving patient outcomes and experiences. Financial details of the deal were not disclosed.
“I’m incredibly proud that our platform can help sift through the noise and identify doctors at the forefront of their fields. He founded the company after his brother was diagnosed with a rare cancer. With Phreesia’s size, scale and experience, we’re now going to be able to reach many more people, which is very exciting.”
– MediFind CEO Patrick Howie
“At Phreesia, we’re always thinking about how to arm patients with the right tools and relevant information, whether that’s a message at the point of care to speed a rare-disease diagnosis, a reminder to schedule overdue preventive screening, or educational content about vaccine safety and effectiveness.”
– David Linetsky, an SVP at Phreesia
